Landmark‐based auto‐contouring of clinical target volumes for radiotherapy of nasopharyngeal cancer

Abstract

AbstractBackgroundThe delineation of clinical target volumes (CTVs) for radiotherapy for nasopharyngeal cancer is complex and varies based on the location and extent of disease.PurposeThe current study aimed to develop an auto‐contouring solution following one protocol guidelines (NRG‐HN001) that can be adjusted to meet other guidelines, such as RTOG‐0225 and the 2018 International guidelines.MethodsThe study used 2‐channel 3‐dimensional U‐Net and nnU‐Net framework to auto‐contour 27 normal structures in the head and neck (H&N) region that are used to define CTVs in the protocol. To define the CTV‐Expansion (CTV1 and CTV2) and CTV‐Overall (the outer envelope of all the CTV contours), we used adjustable morphological geometric landmarks and mimicked physician interpretation of the protocol rules by partially or fully including select anatomic structures. The results were evaluated quantitatively using the dice similarity coefficient (DSC) and mean surface distance (MSD) and qualitatively by independent reviews by two H&N radiation oncologists.ResultsThe auto‐contouring tool showed high accuracy for nasopharyngeal CTVs. Comparison between auto‐contours and clinical contours for 19 patients with cancers of various stages showed a DSC of 0.94 ± 0.02 and MSD of 0.4 ± 0.4 mm for CTV‐Expansion and a DSC of 0.83 ± 0.02 and MSD of 2.4 ± 0.5 mm for CTV‐Overall. Upon independent review, two H&N physicians found the auto‐contours to be usable without edits in 85% and 75% of cases. In 15% of cases, minor edits were required by both physicians. Thus, one physician rated 100% of the auto‐contours as usable (use as is, or after minor edits), while the other physician rated 90% as usable. The second physician required major edits in 10% of cases.ConclusionsThe study demonstrates the ability of an auto‐contouring tool to reliably delineate nasopharyngeal CTVs based on protocol guidelines. The tool was found to be clinically acceptable by two H&N radiation oncology physicians in at least 90% of the cases.